Results 31 to 40 of about 24,860,034 (345)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

Nature reviews. Immunology, 2022
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its ...
B. Haynes, K. Wiehe, P. Borrow, K. Saunders, Bette Korber, K. Wagh, A. McMichael, G. Kelsoe, B. Hahn, F. Alt, G. Shaw   +10 more
semanticscholar   +1 more source

Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study

Viruses, 2021
Background: If analytical antiretroviral-treatment (ART) interruption (ATI) might significantly impact quantitative or qualitative peripheral-total HIV-DNA is still debated.
Rossana Scutari, Valentino Costabile, Laura Galli, Maria Concetta Bellocchi, Luca Carioti, Silvia Barbaliscia, Andrea Poli, Andrea Galli, Carlo Federico Perno, Maria Mercedes Santoro, Antonella Castagna, Francesca Ceccherini-Silberstein, Claudia Alteri, Vincenzo Spagnuolo   +13 more
doaj   +1 more source

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

New England Journal of Medicine, 2021
BACKGROUND Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the ...
L. Corey, P. Gilbert, M. Juraska, D. Montefiori, L. Morris, S. Karuna, Srilatha Edupuganti, N. Mgodi, Allan C. deCamp, Erika Rudnicki, Yunda Huang, P. Gonzales, R. Cabello, C. Orrell, J. Lama, F. Laher, E. Lazarus, Jorge Sanchez, I. Frank, J. Hinojosa, M. Sobieszczyk, Kyle Marshall, P. Mukwekwerere, J. Makhema, L. Baden, J. Mullins, C. Williamson, J. Hural, M. McElrath, Carter Bentley, Simbarashe Takuva, Margarita M Gomez Lorenzo, D. Burns, Nicole Espy, A. Randhawa, Nidhi K. Kochar, E. Piwowar-Manning, D. Donnell, N. Sista, P. Andrew, J. Kublin, G. Gray, J. Ledgerwood, J. Mascola, M. Cohen   +44 more
semanticscholar   +1 more source

HIV-1 Nef: at the crossroads [PDF]

Retrovirology, 2008
The development of anti-virals has blunted the AIDS epidemic in the Western world but globally the epidemic has not been curtailed. Standard vaccines have not worked, and attenuated vaccines are not being developed because of safety concerns. Interest in attenuated vaccines has centered on isolated cases of patients infected with HIV-1 containing a ...
John L. Foster, J. Victor Garcia
openaire   +4 more sources

Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages

Retrovirology, 2019
Background Mammalian cells harbour RNA quality control and degradative machineries such as nonsense-mediated mRNA decay that target cellular mRNAs for clearance from the cell to avoid aberrant gene expression.
Shringar Rao, Raquel Amorim, Meijuan Niu, Yann Breton, Michel J. Tremblay, Andrew J. Mouland   +5 more
doaj   +1 more source

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

PLoS ONE, 2015
Introduction The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and
Daniel D. Murray, Kazuo Suzuki, M. Law, J. Trebicka, J. Neuhaus, D. Wentworth, M. Johnson, M. Vjecha, A. Kelleher, S. Emery   +9 more
semanticscholar   +1 more source

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Current Opinion in HIV and AIDS, 2022
PURPOSE OF REVIEW This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.
H. Dvory‐Sobol, Naveed A Shaik, C. Callebaut, M. Rhee   +3 more
semanticscholar   +1 more source

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

New England Journal of Medicine, 2015
BACKGROUND Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of ...
J. Molina, C. Capitant, B. Spire, G. Pialoux, L. Cotte, I. Charreau, C. Tremblay, J. Le Gall, E. Cua, A. Pasquet, F. Raffi, C. Pintado, C. Chidiac, J. Chas, P. Charbonneau, C. Delaugerre, M. Suzan-Monti, B. Loze, J. Fonsart, G. Peytavin, A. Chéret, J. Timsit, G. Girard, N. Lorente, M. Préau, J. Rooney, M. Wainberg, D. Thompson, W. Rozenbaum, V. Doré, L. Marchand, M. Simon, N. Etien, J. Aboulker, L. Meyer, J. Delfraissy   +35 more
semanticscholar   +1 more source

Acute HIV-1 Infection [PDF]

New England Journal of Medicine, 2011
In 2009, the United Nations estimated that 33.2 million people worldwide were living with human immunodeficiency virus type 1 (HIV-1) infection and that 2.6 million people had been newly infected.1 The need for effective HIV-1 prevention has never been greater.
Cohen, MS, Shaw, G, Mcmichael, A, Haynes, B   +3 more
openaire   +4 more sources

Evolutionary interplay between viruses and R‐loops

FEBS Letters, EarlyView.
Viruses interact with specialized nucleic acid structures called R‐loops to influence host transcription, epigenetic states, latency, and immune evasion. This Perspective examines the roles of R‐loops in viral replication, integration, and silencing, and how viruses co‐opt or avoid these structures.
Zsolt Karányi, Zita Képes, Zoltán Szabó, Eszter Csoma, Lóránt Székvölgyi   +4 more
wiley   +1 more source